title: The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart.
abstract: Electropharmacological effect of the antipsychotic and antiemetic drug prochlorperazine was assessed using the halothane-anesthetized in vivo canine model (n = 5). Up to 10 times higher than the clinically relevant doses of prochlorperazine (< or = 3 mg/kg, i.v.) did not induce cardiohemodynamic collapse in the model. Meanwhile, clinically relevant to supratherapeutic doses (0.3 - 3 mg/kg, i.v.) prolonged the ventricular repolarization period in a dose-related and reverse-use dependent manner that could become proarrhythmic substrates. Thus, caution has to be paid on the use of prochlorperazine particularly for patients with risks of the elevated plasma drug concentration, compromised cardiac repolarization, and/or frequent ventricular premature beats.
authors.affiliation: Department of Medicine, Koshu Rehabilitation Hospital, Faefuki-city, Japan.
authors.forename: Yoshioki
authors.initials: Y
authors.lastname: Satoh
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sugiyama
authors.forename: Akira
authors.initials: A
authors.lastname: Takahara
authors.forename: Kentaro
authors.initials: K
authors.lastname: Ando
authors.forename: Kai
authors.initials: K
authors.lastname: Wang
authors.forename: Sachiko
authors.initials: S
authors.lastname: Honsho
authors.forename: Keitaro
authors.initials: K
authors.lastname: Hashimoto
mesh_terms: D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D000932:Antiemetics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002036:Bundle of His / Q000187:drug effects / Q000502:physiology; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D002304:Cardiac Pacing, Artificial / Q000379:methods; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004562:Electrocardiography / Q000379:methods; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006352:Heart Ventricles / Q000187:drug effects*; D007262:Infusions, Intravenous; D008297:Male; D011346:Prochlorperazine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D012032:Refractory Period, Electrophysiological / Q000187:drug effects / Q000502:physiology; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology; D016276:Ventricular Function; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology; D017725:Ventricular Pressure / Q000187:drug effects / Q000502:physiology
chemical_list: D000932:Antiemetics; D014150:Antipsychotic Agents; D011346:Prochlorperazine